About Ionix Pharmaceuticals
Ionix Pharmaceuticals is a Healthcare company based in Cambridge (United Kingdom) founded in 2001, and was acquired by Vernalis in July 2005. Analgesic medicines for acute and chronic pain are developed. Its focus areas include Life Sciences, Neurology, Drugs and Pain.
Company details
Ionix Pharmaceuticals was founded in 2001 in Cambridge, United Kingdom, within the pharmaceuticals sector. Focus is placed on developing treatments for pain related to trauma, surgery, and conditions like arthritis, diabetes, and multiple sclerosis. Technology combines drug delivery systems with proprietary targets. The lead candidate, IX-1003, is an intranasal buprenorphine formulation in clinical trials for post-operative pain. Operations center on advancing these analgesics through development stages.
- Headquarters Cambridge, United Kingdom
- Stage Acquired
- SectorsHealthcare
- Website ionixpharma.com
- Acquired by Vernalis (Jul 2005)
Investors in Ionix Pharmaceuticals
Ionix Pharmaceuticals has secured backing from 1 investor. Prominent investors backing the company include Vernalis.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Vernalis is engaged in structure-based drug discovery collaborations. | 1999 | vernalis.com | Wokingham, United Kingdom |
Investor details for Ionix Pharmaceuticals
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Ionix Pharmaceuticals
2 dated milestones of Ionix Pharmaceuticals across 4 years, from founding to its latest funding, stage changes and deals.
- Founded Ionix Pharmaceuticals is founded.
- Exit Acquired by Vernalis.
Top companies in Life Sciences Platforms & Tools
3 companies that operate in the same segment as Ionix Pharmaceuticals (Life Sciences Platforms & Tools) in United Kingdom, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.34 B | USD 301.49 M | 1,372 | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | |||
Biological reagents and antibodies are developed for life science research. | 1998 | Cambridge, Cambridgeshire, United Kingdom | USD 78.8 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Ionix Pharmaceuticals
Ionix Pharmaceuticals was founded in 2001.
Ionix Pharmaceuticals is headquartered in Cambridge, United Kingdom. It is registered at Cambridge, Cambridgeshire, United Kingdom.
Ionix Pharmaceuticals was founded in 2001 in Cambridge, United Kingdom, within the pharmaceuticals sector. Focus is placed on developing treatments for pain related to trauma, surgery, and conditions like arthritis, diabetes, and multiple sclerosis. Technology combines drug delivery systems with proprietary targets. The lead candidate, IX-1003, is an intranasal buprenorphine formulation in clinical trials for post-operative pain. Operations center on advancing these analgesics through development stages.
Ionix Pharmaceuticals has 1 investor. Key investors include Vernalis.
Yes. Ionix Pharmaceuticals was acquired by Vernalis in July 2005.